Abstract 5437
Background
Apoptosis has a central role in the process of oral mucositis and can be sustained by proinflammatory cytokines. Some studies have demonstrated increased levels of tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β) and interleukin 6 (IL-6) in saliva after radiotherapy and chemotherapy, which has been associated to severe oral mucositis. However, little is known about the role of these cytokines in the pro and anti-apoptosis process of oral cells exposed to antineoplastic agents. The aim of this study was to verify whether there was an association of salivary cytokines with oral cells exhibiting apoptosis or anti-apoptotic Bcl-2 expression in patients who experienced oral mucositis during hematopoietic cell transplantation (HCT).
Methods
We collected saliva and oral mucosa cells from 77 HCT patients before the conditioning (T0), during the neutropenia period (T1), and after the marrow recovery (T2). We quantified the oral exfoliated cells exhibiting TUNEL positivity and immunocytochemical expression of Bcl-2. We also determined the salivary levels of TNF-α, IL-1β, and IL-6 in the three periods.
Results
The number of cells exhibiting positivity to TUNEL (p = 0.021) and Bcl-2 (p = 0.020) increased from T0 to T2. The levels of TNF-α increased significantly from T0 to T1 (p < 0.001). There were no significant alterations of IL-1β and IL-6 comparing the three periods. There was a significant positive correlation between TNF-α and TUNEL in T0 (rho=0.277, p = 0.033) and T1 (rho=0.451, p = 0.020). Bcl-2 expression in T1 (rho=--0.335, p = 0.048) was negatively correlated with time duration of oral mucositis.
Conclusions
Oral cells exhibited apoptosis even after the marrow recovery. Oral cells apoptosis was associated with salivary TNF-α during the neutropenia period. Oral cells also exhibited high expression of antiapoptotic protein Bcl-2, which was inversely proportional to the duration of oral mucositis, suggesting the activation of a surveillance mechanism in the oral cells. Alterations on salivary TNF-α during the HCT may have a putative role in the apoptosis presented in oral mucositis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Israelita Albert Einstein.
Funding
São Paulo Research Foundation (2016/03650-4) and AmigoOH - Brazil.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract